Multiple class-action lawsuits regarding the marketing of GLP-1 RAs were transferred to be heard together as part of multidistrict litigation (MDL). More information on the MDL is below.
In Re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation
24-md-3094, E.D. Penn.
(2024)
Ozempic, Wegovy, Rybelsus, Saxenda, Victoza, Mounjaro, Zepbound, Trulicity and other GLP-1 RA medications
Marketing products as weight-loss medications without adequately disclosing that many people stop using them due to their side effects, the medications do not result in meaningful weight loss for up to 15 percent of people, the average weight loss is approximately 10 percent of a person’s body weight, and people need to stay on them to maintain their weight loss
Pending
MADISON, CONN. April 9, 2025 — Dutch automaker Stellantis has paused its new “American Born” campaign after getting called out by consumer advocacy organization truthinadvertising.org (TINA.org). Released in the wake…
New ads came and went amid increased attention on U.S. auto manufacturing industry.
Patrick Coffee, The Wall Street Journal
Patrick Coffee, The Wall Street Journal
Pet-safe and eco-friendly claims may be streaky.